These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 6429814)

  • 41. Immunogenicity, safety, and antibody persistence at 3, 5, and 10 years postvaccination in adolescents randomized to booster immunization with a combined tetanus, diphtheria, 5-component acellular pertussis, and inactivated poliomyelitis vaccine administered with a hepatitis B virus vaccine concurrently or 1 month apart.
    Embree J; Law B; Voloshen T; Tomovici A
    Clin Vaccine Immunol; 2015 Mar; 22(3):282-90. PubMed ID: 25540274
    [TBL] [Abstract][Full Text] [Related]  

  • 42. WHO activities towards the three Rs in the development and control of biological products.
    Milstien J; Grachev V; Padilla A; Griffiths E
    Dev Biol Stand; 1996; 86():31-9. PubMed ID: 8785961
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Immunogenicity and safety of one dose of diphtheria, tetanus, acellular pertussis and poliomyelitis vaccine (Repevax®) followed by two doses of diphtheria, tetanus and poliomyelitis vaccine (Revaxis®) in adults aged ≥ 40 years not receiving a diphtheria- and tetanus-containing vaccination in the last 20 years.
    Dominicus R; Galtier F; Richard P; Baudin M
    Vaccine; 2014 Jun; 32(31):3942-9. PubMed ID: 24852717
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Co-administration of a novel Haemophilus influenzae type b and Neisseria meningitidis serogroups C and Y-tetanus toxoid conjugate vaccine does not interfere with the immune response to antigens contained in infant vaccines routinely used in the United States.
    Marshall GS; Marchant CD; Blatter M; Friedland LR; Aris E; Miller JM
    Hum Vaccin; 2011 Feb; 7(2):258-64. PubMed ID: 21307655
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Diphtheria-tetanus-acellular pertussis and inactivated poliovirus vaccines given separately or combined for booster dosing at 4-6 years of age.
    Black S; Friedland LR; Ensor K; Weston WM; Howe B; Klein NP
    Pediatr Infect Dis J; 2008 Apr; 27(4):341-6. PubMed ID: 18316985
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Immunogenicity and reactogenicity of Infanrix™ when co-administered with meningococcal MenACWY-TT conjugate vaccine in toddlers primed with MenHibrix™ and Pediarix™.
    Leonardi M; Latiolais T; Sarpong K; Simon M; Twiggs J; Lei P; Rinderknecht S; Blatter M; Bianco V; Baine Y; Friedland LR; Baccarini C; Miller JM
    Vaccine; 2015 Feb; 33(7):924-32. PubMed ID: 25305567
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Two injections of diphtheria-tetanus-pertussis-polio vaccine as the backbone of a simplified immunization schedule in developing countries.
    Cohen H; Nagel J
    Rev Infect Dis; 1984; 6 Suppl 2():S350-1. PubMed ID: 6610910
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Safety, reactogenicity and immunogenicity of a combined hexavalent tetanus, diphtheria, acellular pertussis, hepatitis B, inactivated poliovirus vaccine and Haemophilus influenzae type b conjugate vaccine, for primary immunization of infants.
    Zepp F; Knuf M; Heininger U; Jahn K; Collard A; Habermehl P; Schuerman L; Sänger R
    Vaccine; 2004 Jun; 22(17-18):2226-33. PubMed ID: 15149781
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Industrial-scale production of inactivated poliovirus vaccine prepared by culture of Vero cells on microcarrier.
    Montagnon BJ; Fanget B; Vincent-Falquet JC
    Rev Infect Dis; 1984; 6 Suppl 2():S341-4. PubMed ID: 6740071
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Immunogenicity and safety of primary and booster vaccination with 2 investigational formulations of diphtheria, tetanus and Haemophilus influenzae type b antigens in a hexavalent DTPa-HBV-IPV/Hib combination vaccine in comparison with the licensed Infanrix hexa.
    Vesikari T; Rivera L; Korhonen T; Ahonen A; Cheuvart B; Hezareh M; Janssens W; Mesaros N
    Hum Vaccin Immunother; 2017 Jul; 13(7):1505-1515. PubMed ID: 28340322
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Immunological persistence in 5 y olds previously vaccinated with hexavalent DTPa-HBV-IPV/Hib at 3, 5, and 11 months of age.
    Silfverdal SA; Assudani D; Kuriyakose S; Van Der Meeren O
    Hum Vaccin Immunother; 2014; 10(10):2795-8. PubMed ID: 25483640
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Antibody response to measles vaccine with DTPP.
    John TJ; Selvakumar R; Balrai V; Simoes EA
    Am J Dis Child; 1987 Jan; 141(1):14. PubMed ID: 3491536
    [No Abstract]   [Full Text] [Related]  

  • 53. Antibody persistence after a primary series of a new DTaP-IPV-Hep B-PRP-T combined vaccine or separate DTaP-IPV//PRP-T and hepatitis B vaccines at 2, 4, and 6 months of age and the effect of a subsequent DTaP-IPV//PRP-T booster vaccination at 18 months of age in healthy Argentinean infants.
    Tregnaghi M; Zambrano B; Santos-Lima E
    Pediatr Infect Dis J; 2012 Jan; 31(1):e24-30. PubMed ID: 22157567
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Inactivated poliovirus vaccine and test development at Connaught Laboratories Ltd.
    Von Seefried A; Chun JH; Grant JA; Letvenuk L; Pearson EW
    Rev Infect Dis; 1984; 6 Suppl 2(Suppl 2):S345-9. PubMed ID: 6330837
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A combined Haemophilus influenzae type B Neisseria meningitidis serogroup C tetanus toxoid conjugate vaccine is immunogenic and well-tolerated when coadministered with diphtheria, tetanus, acellular pertussis hepatitis B-inactivated poliovirus at 3, 5 and 11 months of age: results of an open, randomized, controlled study.
    Vesikari T; Forstén A; Desole MG; Ferrera G; Caubet M; Mesaros N; Boutriau D
    Pediatr Infect Dis J; 2013 May; 32(5):521-9. PubMed ID: 23190785
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Immunogenicity and reactogenicity of diphtheria, tetanus and pertussis toxoids combined with inactivated polio vaccine, when administered concomitantly with or as a diluent for a Hib conjugate vaccine.
    Knutsson N; Trollfors B; Taranger J; Bergfors E; Sundh V; Lagergård T; Ostergaard E; Cicirello H; Käyhty H
    Vaccine; 2001 Aug; 19(31):4396-403. PubMed ID: 11483264
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Immunogenicity and safety of a trivalent tetanus, low dose diphtheria, inactivated poliomyelitis booster compared with a standard tetanus, low dose diphtheria booster at six to nine years of age. Munich Vaccine Study Group.
    Stojanov S; Liese JG; Bendjenana H; Harzer E; Barrand M; Jow S; Dupuy M; Belohradsky BH
    Pediatr Infect Dis J; 2000 Jun; 19(6):516-21. PubMed ID: 10877165
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Deleterious effect of thimerosal on the potency of inactivated poliovirus vaccine.
    Sawyer LA; McInnis J; Patel A; Horne AD; Albrecht P
    Vaccine; 1994 Jul; 12(9):851-6. PubMed ID: 7526574
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Vaccine policy likely to be reassessed in 1990s when polio-DTP combination becomes available.
    Marwick C
    JAMA; 1988 Jun; 259(24):3523-4. PubMed ID: 3259637
    [No Abstract]   [Full Text] [Related]  

  • 60. Safety, immunogenicity and persistence of immune response to the combined diphtheria, tetanus, acellular pertussis, poliovirus and Haemophilus influenzae type b conjugate vaccine (DTPa-IPV/Hib) administered in Chinese infants.
    Li Y; Li RC; Ye Q; Li C; Liu YP; Ma X; Li Y; Zhao H; Chen X; Assudani D; Karkada N; Han HH; Van Der Meeren O; Mesaros N
    Hum Vaccin Immunother; 2017 Mar; 13(3):588-598. PubMed ID: 27768515
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.